Obviousness

Obviousness Analysis of U.S. Patent 12,037,567

This analysis examines the patentability of the claims in U.S. Patent 12,037,567 ("the '567 patent") in light of prior art, under the criteria of 35 U.S.C. § 103, which prohibits the patenting of an invention if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art.

1. Understanding the Claims and the Person of Ordinary Skill in the Art

The independent claims of the '567 patent (Claims 1 and 11) are directed to a method of either increasing or maintaining ketone bodies in a subject by administering a beverage containing at least 0.5% by volume of D-1,3-butanediol, with no, or substantially no, L-1,3-butanediol. The claims also allow for the optional inclusion of other ketogenic compounds, such as D-ethyl 3-hydroxybutyrate, and beta-hydroxybutyrate salts, as well as ethanol. The stated goal is to achieve or maintain blood ketone levels above 0.5 mmol/L.

A person of ordinary skill in the art (POSA) for this invention would likely be a food scientist, a biochemist, or a beverage formulation chemist with experience in functional foods and beverages, particularly those related to nutritional supplements and metabolic health. This individual would have a solid understanding of ketogenic diets, ketone bodies, and their physiological effects.

2. Key Elements of the Claims for Obviousness Analysis

The core components of the invention, as defined by the independent claims, are:

• A method of increasing or maintaining ketone bodies.
• The use of a beverage as the delivery vehicle.
• The inclusion of D-1,3-butanediol as the primary active ingredient.
• A minimum concentration of 0.5% by volume of D-1,3-butanediol.
• The substantial exclusion of L-1,3-butanediol.
• The goal of achieving or maintaining blood ketone levels above 0.5 mmol/L.

3. Analysis of Prior Art and Motivation to Combine

Several prior art references, when considered in combination, suggest that the invention claimed in the '567 patent would have been obvious to a POSA.

• US Patent 9,138,420 (D'Agostino et al., "the '420 patent"): This patent, with a priority date of March 19, 2013, is highly relevant. It explicitly teaches compositions and methods for producing "elevated and sustained ketosis." The '420 patent discloses the use of various ketone precursors, including 1,3-butanediol, in oral compositions to elevate blood ketone levels. Although the '420 patent does not specify the D-isoform of 1,3-butanediol, the general concept of using this compound to induce ketosis is well-established in this reference.

• US Patent 6,207,856 (Veech, "the '856 patent"): With a priority date of March 17, 1997, this patent discloses therapeutic compositions containing ketone bodies and their precursors. The '856 patent teaches the use of these compounds for a variety of therapeutic purposes and discusses their metabolic effects. While it does not focus on a beverage for general functional use, it provides foundational knowledge about the physiological effects of ketone precursors.

• WO 2014/153416 (D'Agostino et al.): This international application, which is related to the '420 patent, further elaborates on compositions for producing ketosis. It discusses the use of ketone esters and other precursors in nutritional supplements. This reference reinforces the idea that various ketone precursors, including 1,3-butanediol, were known to be effective in raising blood ketone levels when consumed orally.

4. Argument for Obviousness

A strong argument for the obviousness of the '567 patent's claims can be constructed as follows:

Motivation to Combine: A POSA, aware of the growing interest in ketogenic diets for health and performance benefits, would have been motivated to develop a convenient, palatable, and effective way to induce or maintain ketosis. The '420 patent and its related publications clearly establish that 1,3-butanediol is an effective ketone precursor. The logical next step for a POSA would be to formulate this compound into a beverage, a common and consumer-friendly delivery format for functional ingredients.

Reasonable Expectation of Success: Given the disclosures in the prior art, a POSA would have had a reasonable expectation of success in creating a ketogenic beverage. The '420 patent demonstrates that oral consumption of 1,3-butanediol leads to a predictable increase in blood ketone levels. The challenge would then become one of formulation—ensuring palatability and stability—rather than one of inventive concept. The dependent claims of the '567 patent, which add flavoring agents and address carbohydrate content, are standard considerations in beverage formulation and do not represent a non-obvious step.

The D-Isomer Limitation: The '567 patent's claims are specific to the D-isomer of 1,3-butanediol. However, it was well-known in the art at the time of the invention that the D-isomer of many biologically active compounds is the more effective or metabolically preferred form. A POSA, seeking to optimize the ketogenic effect of a 1,3-butanediol beverage, would have been naturally led to investigate the properties of the individual isomers. The selection of the D-isomer would have been a routine step in product optimization, not an inventive leap.

Conclusion on Obviousness

The claims of US patent 12,037,567 appear to be vulnerable to an obviousness challenge under 35 U.S.C. § 103. The prior art, particularly the '420 patent, had already taught the core concept of using 1,3-butanediol as an oral supplement to induce ketosis. The subsequent steps of formulating this compound into a beverage and selecting the more biologically active D-isomer would have been obvious to a person of ordinary skill in the art seeking to create a consumer-friendly ketogenic product. The claimed invention, therefore, represents an obvious combination of known elements with a predictable outcome.